Details of the Drug

General Information of Drug (ID: DMK3RL8)

Drug Name

Somatropin intranasal rhGH

Synonyms

ALTU-238; CP-024; HGH-191; Somatropin (intranasal); Human growth hormone (crystalline), Altus/Genentech; RhGH (oral, eligen), Novartis; Somatropin (crystalline), Altus/Genentech; Somatropin (sustained release, subcutaneous), Althea; Humatrope (oral, CADDYS), Lilly/Emisphere; Recombinant human growth hormone (oral, CADDYS), Lilly/Emisphere; RhGH (oral, CADDYS), Lilly/Emisphere; RhGH (oral, eligen), Emisphere/Novartis; Somatropin (nasal spray, CriticalSorb, growth hormone deficiency), Critical Pharmaceuticals; Somatropin (oral, CADDYS), Lilly/Emisphere; Somatropin (sustained release, subcutaneous), Altus/Genentech; Human growth hormone, (sustained release, subcutaneous), Altus/Genentech

Indication

Disease Entry	ICD 11	Status	REF
Growth hormone deficiency	5A61.3	Phase 2	[1]

Cross-matching ID

TTD ID: D0C9SW

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatotropin (GH1)	TTT3YKH	SOMA_HUMAN	Modulator	[2]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT00837863) Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency. U.S. National Institutes of Health.
2	Long-term efficacy and safety of somatropin for adult growth hormone deficiency.Treat Endocrinol.2003;2(2):109-20.